BetterLife Pharma Inc. BETRF
0.16 USD 0.00 (-1.68%)
Nov 5, 2026, 2:47 PM EST
0.158 Day range 0.16
0.028 52-week range 0.331
- YTD
- +393.75%
- 1 year
- +251.11%
- Market cap
- 97.65M
- EPS (ttm)
- -0.02
- YTD return
- +393.75%
- 1-year return
- +251.11%
- Volume
- 15.00K
- Avg volume
- 120.90K
- Open
- 0.16
- Previous close
- 0.1607
- Day's range
- 0.158 – 0.16
- 52-week range
- 0.028 – 0.331
- Earnings date
- Jan 3, 2025
6M +0.1100 (+229.17%)
Next earnings
Jan 3, 2025
Expected Jan 3, 2025. Consensus EPS estimate 0.00.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 3, 2025 | Oct 1, 2024 | 0.00 | — | — | — |
| Sep 25, 2024 | Jul 1, 2024 | 0.00 | -0.01 | — | — |
| Jun 27, 2024 | Apr 1, 2024 | 0.00 | -0.01 | — | — |
| May 29, 2024 | Jan 1, 2024 | 0.00 | -0.01 | — | — |
| Dec 29, 2023 | Oct 1, 2023 | 0.00 | 0.00 | — | — |
| Sep 27, 2023 | Jul 1, 2023 | 0.00 | -0.01 | — | — |
News
BetterLife Pharma Appoints Henry Chow, CPA, CA, to Board of Directors 
BetterLife Pharma Appoints LifeSci Advisors as Investor Relations Firm 
BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board 
BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations 
BetterLife Pharma Inc. (OTCMKTS:BETRF) Stock Short Interest Report for September 
BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair 
BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha 
BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting 
BetterLife Pharma Inc. (OTCMKTS:BETRF) Sees Large Decrease in Short Interest 
BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
Your note
Sign in to keep a note on BETRF — it syncs with the Stock Master app.